Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 107

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 107
---
 | initiation of investigations by regulators; |

| ● | costs to defend the related litigation; |

| ● | a diversion of management’s time and our resources; |

| ● | substantial monetary awards to trial participants or patients; |

| ● | product recalls, withdrawals or labeling, marketing or promotional 
 restrictions;                                                      |

| ● | loss of revenue; |

| ● | exhaustion of any available insurance and our capital resources; |

| ● | the inability to commercialize any drug candidate; and |

| ● | a decline in the price of Aptorum Class A ordinary shares. |

We shall seek to obtain the
appropriate insurance once our candidates are ready for clinical trial. However, our inability to obtain sufficient product liability
insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of
drugs we develop, alone or with collaborators. We currently do not have in place product liability insurance and although we plan to have
in place such insurance as and when the products are ready for commercialization, as well as insurance covering clinical trials, the amount
of such insurance coverage may not be adequate, we may be unable to maintain such insurance, or we may not be able to obtain additional
or replacement insurance at a reasonable cost, if at all. Our insurance policies may also have various exclusions, and we may be subject
to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement
that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital
to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such
indemnification may not be available or adequate should any claim arise.

Additionally, we may be sued
if the products that we commercialize, market or sell cause or are perceived to cause injury or are found to be otherwise unsuitable,
and may result in:

| ● | decreased demand for those products; |

| ● | damage to our reputation; |

| ● | costs incurred related to product recalls; |

| ● | limiting our opportunities to enter into future commercial partnership; 
 and                                                                     |

| ● | a decline in the price of Aptorum Class A ordinary shares. |

<div align='center'>57</div>

Our insurance coverage may be inadequate to protect us against losses.

We currently maintain property
insurance for our office premises. We hold employer’s